Healthcare
SHS sells ProBioGen to Minapharm Pharmaceuticals for €30.4 million
SHS Beteiligungsmanagement has sold ProBioGen to Cairo-based strategic investor Minapharm Pharmaceuticals.
Truffle Capital floats Carmat
Artificial heart developer Carmat has launched an IPO on the Alternext of NYSE-Euronext Paris, looking for €15m.
Vesalius and LRM back Complix
Vesalius Biocapital and LRM have backed Belgian pharmaceutical company, Complix NV.
Warburg Pincus sponsored Tornier applies for $205m IPO
Private equity-backed Tornier BV has plans to raise around $205m by listing on Nasdaq Global Markets.
Kernel Capital invests €750,000 in Bioatlantis
Kernel Capital has made a €750,000 investment in BioAtlantis Limited, an Irish biotechnology company based in the Kerry Technology Park in Tralee.
Truffle Capital et al. invest €4.8m in Pharnext
French biopharmaceutical company Pharnext has closed a €4.8m series-A round of funding from Truffle Capital, Aurinvest Capital 2, Financière Boscari and three individual investors.
Nycomed requests further covenant relief
Swiss private equity-backed drug company Nycomed has asked its lenders for covenant relief as it looks at ways of managing its debts.
CDC Entreprises et al. inject €12m into Cytheris
French biopharmaceutical company Cytheris has completed a €12m series-D round of financing.
Auctus acquires rehabilitation clinics
Auctus Capital Partners has acquired eight rehabilitation clinics from Marseille-Kliniken AG for an undisclosed amount. Following the transaction, the group of clinics will trade as Celenus-Kliniken GmbH.
Nordic Capital acquires Handicare
Nordic Capital has acquired Handicare from Herkules Capital in a secondary buyout.
Strong private equity interest for Catalpa
According to reports six private equity houses have made a first offer for Dutch childcare provider Catalpa.
Weinberg Capital backs Pharma Omnium in Cellvir acquisition
French laboratory Pharma Omnium International, owned by Weinberg Capital Partners, has acquired biotech company Cellvir.
Industry veterans launch new Russia fund, Elbrus Capital
Three industry veterans are launching a new Russian private equity investment company, Elbrus Capital, after they bought out the assets of Renaissance Private Equity from the Renaissance Group at the end of 2009.
Novartis Venture et al. invest CHF 5m in NanoPowers
Novartis Venture Funds has led a CHF 5m series-A funding round in medical device company NanoPowers. Initiative Capital Romandie (ICR) and Fribourg-based Gran Plasa SA also invested.
Centocor acquires RespiVert from Advent
Advent Venture Partners and other investors have sold their stakes in drug discovery company RespiVert.
Catapult invests £1.1m in Biofortuna
Catapult Venture has invested £1.1m into a molecular diagnostics company Biofortuna Ltd.
AAC Capital buys UK pharma company for £100m
Martindale Pharmaceuticals, the UK based methadone maker, has been bought by AAC Capital Partners for £100m.
NorthStar leads £1.6m investment in Reinnervate
NorthStar Equity Investors has led a £1.6m funding round for start-up biotechnology company, Reinnervate.
TVM Capital restructures; hires Schuler
TVM Capital has reorganised its life science investment practice. In the future, the firm will operate two dedicated teams with differentiated investment concepts to invest in pharmaceutical, biopharmaceutical, medical technologies (medtech) and healthcare...
NGN Capital leads €33m series-D round for NOXXON Pharma AG
NGN Capital has led a €33m series-D round in NOXXON Pharma. NGN is a new investor and was joined by existing investors TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin GmbH, Dow...
NorthStar leads £1.6m round in Reinnervate
NorthStar Equity Investors has led an investment round of over £1.6m in biotech start-up Reinnervate Limited.
Ventech invests €10m in Funxional Therapeutics
French private equity firm Ventech entered the series-B financing round as a new investor, alongside existing backers Index Ventures and Novo A/S.
Sarsia Seed invests in APIM Therapeutics
Sarsia Seed has invested NOK 3.5m in Norwegian drug developer, APIM Therapeutics AS.
PAI interested in Cerba European Lab buyout
PAI partners has entered into exclusive discussions with IK Investment Partners and management to acquire a majority stake in Cerba European Lab SAS.